Taiwan Liposome Company (TLC) Pops 85% Amid Submitting New Drug

Shares of NASDAQ: TLC instantly jumps from $5.16 to $9.45 in the premarket after the management announced submitting TLC19 Hydroxychloroquine Liposome Inhalation Suspension to the Taiwan Food and Drug Administration (TFDA) for the healing COVID-19 victims.

TLC struggles in the stock market since July 6 when shares cost around $6. The penny stock now becomes over $9 and perhaps, at the end of the day investors could be willing to buy it for $11 due to increasing demand for the cheap shares.

It is not late to join the TLC band as the existing drug will be tested clinically and may be improved. Hence, after hearing good news about tests TLC, most probably, will rise higher.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life